Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
Launched by VALENCIA TECHNOLOGIES CORPORATION · Jun 3, 2018
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Primary Inclusion Criteria:
- • 1. Women and men between 18 and 80 years old.
- • 2. Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and stress incontinence with a predominant urgency component (selfreported), for at least 6 months.
- • 3. Individual is without pharmacological treatment of overactive bladder (antimuscarinics and beta-3 agonists).
- • 4. Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or percutaneous tibial nerve stimulation.
- Primary Exclusion Criteria:
- • 1. Predominant stress urinary incontinence with more than 1/3 stress urinary incontinent episodes when compared to total urinary incontinent episodes.
- • 2. Clinically significant bladder outlet obstruction.
- • 3. Clinically significant pelvic organ prolapse beyond the hymenal ring.
- • 4. Inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.
About Valencia Technologies Corporation
Valencia Technologies Corporation is a pioneering clinical trial sponsor focused on advancing innovative medical technologies to improve patient outcomes. With a commitment to excellence in research and development, Valencia Technologies specializes in the design and execution of clinical trials that address unmet medical needs across various therapeutic areas. The company leverages cutting-edge methodologies and a robust network of clinical sites to ensure rigorous study protocols, efficient data collection, and comprehensive analysis. Valencia Technologies is dedicated to fostering collaboration among stakeholders, including healthcare professionals and regulatory bodies, to accelerate the delivery of safe and effective treatments to patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Diego, California, United States
Downey, California, United States
Greensboro, North Carolina, United States
Santa Barbara, California, United States
Columbia, South Carolina, United States
New York, New York, United States
Norwalk, Connecticut, United States
Owings Mills, Maryland, United States
Omaha, Nebraska, United States
Waterloo, Iowa, United States
Allentown, Pennsylvania, United States
Redwood City, California, United States
Englewood, Colorado, United States
Naples, Florida, United States
Skokie, Illinois, United States
Patients applied
Trial Officials
Scott MacDiarmid, MD
Principal Investigator
Alliance Urology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials